SYFb566b92e71684afc9fea677d88d86e0fRegistry ID: 2023-505839-12-01|RecruitingPhase 3
the BIRDIE trial
BIomarker-dRiven Dosing Interval Extension of biologics in asthma (the BIRDIE trial)
Loading search results
interventional
N/A
1 country
1
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
Not reported
Date not reportedClick on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
June 23, 2023
Actual (reported)The main study endpoint is the number of injections in the mepolizumab and in the dupilumab intervention group compared to the control groups during the follow-up period.
These entries preserve how the registry describes the intervention. Their treatment roles are shown separately from molecular identities.
Formulated product
Nucala 100 mg powder for solution for injection
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
SOLUTION FOR INJECTION
View registry recordFormulated product
Dupixent 100 mg solution for injection in pre-filled syringe
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
SOLUTION FOR INJECTION
View registry recordThe registry names these ingredients. The formulation’s exact chemical form has not been confirmed.
Nucala 100 mg powder for solution for injection
Named ingredient: mepolizumab
View registry recordDupixent 100 mg solution for injection in pre-filled syringe
Named ingredient: dupilumab
View registry recordSint Franciscus Vlietland Groep Stichting
Rotterdam, 3045 PM, Netherlands
Wetenschapsbureau
First Submitted
June 23, 2023
Download the complete CTIS (EMA) record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: European Medicines Agency (EMA), Clinical Trials Information System (CTIS). Original record and public documents are available on CTIS.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved:
Contact the study team to confirm eligibility.